PHA000215_The Lancet


Issue link:

Contents of this Issue


Page 0 of 13 Reprint Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols, Diego L Cortinovis, Joseph Leach, Jonathan Polikoff , Carlos Barrios, Fairooz Kabbinavar, Osvaldo Arén Frontera, Filippo De Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S Chen, Alan Sandler, David R Gandara, for the OAK Study Group Lancet 2017; 389: 255–65 Previously published online See for WebExtra content Copyright 2017 ELSEVIER LIMITED, 125 London Wall, London EC2Y 5AS, UK. Version verified by CrossMark

Articles in this issue

Links on this page

view archives of PHA000215_The Lancet - Rittmeyer_1510-0318